Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | PPM1G | O15355 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | PPM1A | P35813 | 1/20 | 0.38 |
| ▸ | PTPN9 | P43378 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.38 |
| ▸ | CDC25A | P30304 | 1/20 | 0.34 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8946276 | 0.82 | ACHE (0.40) | PTGESPPM1GALOX5PTPN1KDM5A | |
| SCHEMBL6251453 | 0.80 | GRM2 (0.39) | PTGESPPM1GALOX5PTPN1KDM5A | |
| SCHEMBL29567556 | 0.76 | TDP1 (0.49) | PTGESPPM1GALOX5PTPN1KDM5A | |
| SCHEMBL1611157 | 0.76 | TDP1 (0.49) | PTGESPPM1GALOX5PTPN1KDM5A | |
| SCHEMBL26998250 | 0.75 | IRAK4 (0.40) | — | |
| SCHEMBL9463397 | 0.75 | AKR1C4 (0.44) | PTGESPPM1GALOX5PTPN1KDM5A | |
| SCHEMBL29384232 | 0.75 | IGFBP3 (0.41) | PTGESPPM1GALOX5PTPN1KDM5A | |
| SCHEMBL158714 | 0.75 | IGFBP3 (0.41) | PTGESPPM1GALOX5PTPN1KDM5A | |
| SCHEMBL9381152 | 0.74 | OPRK1 (0.51) | KDM4C | |
| SCHEMBL9441953 | 0.74 | PTGES (0.39) | PTGESPPM1GALOX5PTPN1KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5441963-A | Administering probenecid and derivatives | MERRELL DOW PHARMACEUTICALS (US) | 1995-08-15 | — | — | US | claimed |
| US-5026700-A | Certain quinolines and thienopyridines as excitatory amino acid antagonists | MERRELL DOW PHARMACEUTICALS (US) | 1991-06-25 | — | — | US | claimed |
| US-20160058749-A1 | TREATMENTS FOR NEUROPATHY | CHILDRENS MEDICAL CENTER (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160045487-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-18 | — | — | US | disclosed |
| WO-2014160811-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20110086878-A1 | Treatments for Neuropathy | NIH-DEITR | 2011-04-14 | — | — | US | disclosed |
| US-7863295-B2 | Treatments for neuropathy | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2240177-A2 | TREATMENTS FOR NEUROPATHY | Children's Medical Center Corporation (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009102570-A2 | TREATMENTS FOR NEUROPATHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090203735-A1 | TREATMENTS FOR NEUROPATHY | NIH-DEITR | 2009-08-13 | — | — | US | disclosed |
| US-5914403-A | NOVEL 4-((PYRIDINO-CARBONYL)AMINO)-2-(CARBOXYLIC ACID OR ESTER)-5,6,7,8-OPTIONALLY SUBSTITUTED QUINOLINE COMPOUNDS AS ANTICONVULSANTS | NICHOLS ALFRED C (US) | 1999-06-22 | — | — | US | disclosed |
| US-5783700-A | ANTICONVULSANTS, TREATMENT OF EPILEPSY, NEURODEGENERATIVE DISEASES, ANTIISCHEMIC, INTERACT WITH N-METHYL-D-ASPARTATE (NMDA) RECEPTOR COMPLEX | NICHOLS ALFRED C (US) | 1998-07-21 | — | — | US | disclosed |
| US-5493027-A | ANTIEPILEPTIC AGENTS, NEUROGENATIVE DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1996-02-20 | — | — | US | disclosed |
| US-5441963-A | Administering probenecid and derivatives | MERRELL DOW PHARMACEUTICALS (US) | 1995-08-15 | — | — | US | disclosed |
| EP-0398283-B1 | Excitatory amino acid antagonists | MERRELL DOW PHARMA (US) | 1994-11-02 | — | — | EP | disclosed |
| WO-1994017042-A1 | ANTICONVULSIVE AGENTS AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-08-04 | — | — | WO | disclosed |
| US-5112821-A | Excitatory amino acid antagonists which are certain thienopyridives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-05-12 | — | — | US | disclosed |
| US-5026700-A | Certain quinolines and thienopyridines as excitatory amino acid antagonists | MERRELL DOW PHARMACEUTICALS (US) | 1991-06-25 | — | — | US | disclosed |
| EP-0398283-A1 | Excitatory amino acid antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058749-A1 | TREATMENTS FOR NEUROPATHY | NGF, BDNF, NTRK2 | PTGES 1215/4885PPM1G 3845/4885ALOX5 368/4885 |
| US-20090203735-A1 | TREATMENTS FOR NEUROPATHY | NGF, BDNF, NTRK2 | PTGES 1215/4885PPM1G 3845/4885ALOX5 368/4885 |
| US-20160045487-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | PMP22, GAP43, NGF | PTGES 3086/4885PPM1G 3281/4885ALOX5 395/4885 |
| US-20110086878-A1 | Treatments for Neuropathy | NGF, BDNF, NTRK2 | PTGES 1215/4885PPM1G 3845/4885ALOX5 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.